論文

2017年3月

Clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan project

JOURNAL OF EPIDEMIOLOGY
  • Shigekazu Ukawa
  • ,
  • Koshi Nakamura
  • ,
  • Emiko Okada
  • ,
  • Makoto Hirata
  • ,
  • Akiko Nagai
  • ,
  • Zentaro Yamagata
  • ,
  • Kaori Muto
  • ,
  • Koichi Matsuda
  • ,
  • Toshiharu Ninomiya
  • ,
  • Yutaka Kiyohara
  • ,
  • Yoichiro Kamatani
  • ,
  • Michiaki Kubo
  • ,
  • Yusuke Nakamura
  • ,
  • Akiko Tamakoshi

27
3
開始ページ
S65
終了ページ
S70
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.je.2016.12.008
出版者・発行元
ELSEVIER SCIENCE INC

Background: Prostate cancer is the sixth leading cause of cancer-related deaths in Japan. We aimed to elucidate the clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan (BBJ) project.
Methods: Four thousand, seven hundred and ninety-three patients diagnosed with prostate cancer in the BBJ project were included. Clinical and histopathological data, including causes of death, were analyzed. Relative survival (RS) rates of prostate cancer were calculated.
Results: Four thousand, one hundred and seventy-one prostate cancer patients with available histological data had adenocarcinoma. The mean age of the patients was 72.5 years. The proportion of patients who were non-smokers, non-drinkers, had a normal body mass index, did not exercise, had a normal prostate-specific antigen level, and had a family history of prostate cancer were 30.7%, 28.0%, 66.6%, 58.1%, 67.6%, and 6.5%, respectively. The proportion of patients with Stage II, III, and IV disease were 24.4%, 7.3%, and 4.4%, respectively. After limiting to patients with a time from the initial diagnosis of prostate cancer to entry into the study cohort of <= 90 days (n = 869), the 5-and 10-year RS rates were 96.3% and 100.5%, respectively, although we were unable to consider management strategies due to a plenty of data missing.
Conclusions: We provide an overview of patients with prostate cancer in the BBJ project. Our findings, coupled with those from various high throughput "omics" technologies, will contribute to the implementation of prevention interventions and medical management of prostate cancer patients. (C) 2017 The Authors. Publishing services by Elsevier B.V. on behalf of The Japan Epidemiological Association.

Web of Science ® 被引用回数 : 6

リンク情報
DOI
https://doi.org/10.1016/j.je.2016.12.008
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/28215481
Scopus
https://www.scopus.com/record/display.uri?eid=2-s2.0-85016394019&origin=inward
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000397216800010&DestApp=WOS_CPL
URL
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85016394019&origin=inward